Xcell was established in September 2015 and is engaged in the research, development, and production of cell culture media suitable for advanced biopharmaceuticals (CGT). Based on ACF essential, it has built a cell-customized media development platform technology by incorporating significance scoring data for candidate ingredients specific to different cell types and the know-how gained from the media development process. The company's media development and manufacturing technology has been recognized as a core strategic technology in the "Key Cell and Material Manufacturing Technology for Advanced Biopharmaceutical Production" field by the Ministry of Trade, Industry, and Energy.

XPorT, the main core technology of Xcell Therapeutics, is aimed at developing optimal media from the perspective of users using various cells. Currently, we are developing customized media for various cells by incorporating XPorT technology, and we are building a diverse pipeline by expanding its application. Starting with the launch of serum-free medium for mesenchymal stem cells, we have succeeded in developing and launching chemically defined medium with animal origin free. With the know-how accumulated during these R&D processes and XPorT technology, we have completed the development of medium for DPCs, medium for keratinocytes, and medium for exosomes, and launched the products.

Public

Biotech